Izastobart

依泽苏拜单抗

Report date: 2023/12/29 10:36:58

Base Information

Drug NameIzastobart
Drug Alias NameMOR-210MOR044254TJ 210TJ210001WBP-2191 +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionC5a anaphylatoxin chemotactic receptor antagonists
TargetsC5a anaphylatoxin chemotactic receptor
Therapy Area/IndicationsSolid tumoursAutoimmune DiseasesImmune System Diseases +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMorphosys Ag
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesI-Mab Biopharma Us LtdHuman Immunology Biosciences IncI-Mab Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursAutoimmune DiseasesNeoplasm Metastasis
Inactive IndicationsImmune System DiseasesNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A